A detailed history of Cetera Investment Advisers transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Cetera Investment Advisers holds 1,788 shares of BGNE stock, worth $324,736. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,788
Previous 2,257 20.78%
Holding current value
$324,736
Previous $322,000 24.53%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$143.93 - $224.51 $67,503 - $105,295
-469 Reduced 20.78%
1,788 $401,000
Q2 2024

Aug 22, 2024

SELL
$129.52 - $174.32 $8,548 - $11,505
-66 Reduced 2.84%
2,257 $322,000
Q1 2024

May 24, 2024

BUY
$141.8 - $181.47 $329,401 - $421,554
2,323 New
2,323 $363,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.